Exscientia (NASDAQ:EXAI) Trading 5.7% Higher

Exscientia plc (NASDAQ:EXAI)’s stock price rose 5.7% during mid-day trading on Monday . The company traded as high as $4.35 and last traded at $4.26. Approximately 57,492 shares traded hands during trading, a decline of 92% from the average daily volume of 687,346 shares. The stock had previously closed at $4.03.

Analysts Set New Price Targets

A number of brokerages recently commented on EXAI. Bank of America cut Exscientia from a “buy” rating to a “neutral” rating and lowered their target price for the company from $11.00 to $9.00 in a report on Friday, January 5th. Morgan Stanley restated an “equal weight” rating and set a $7.00 target price on shares of Exscientia in a report on Monday, April 22nd.

Exscientia Stock Up 16.1 %

The business has a fifty day moving average of $5.58 and a 200 day moving average of $5.84. The company has a market capitalization of $565.77 million, a PE ratio of -3.13 and a beta of 0.78. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.05.

Exscientia (NASDAQ:EXAI) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. The business had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $41.63 million. Exscientia had a negative return on equity of 36.44% and a negative net margin of 737.10%. Equities research analysts anticipate that Exscientia plc will post -1.76 EPS for the current year.

Hedge Funds Weigh In On Exscientia

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale acquired a new stake in shares of Exscientia during the 3rd quarter worth about $344,000. Banque Pictet & Cie SA acquired a new stake in shares of Exscientia during the 3rd quarter worth about $1,040,000. China Universal Asset Management Co. Ltd. raised its position in shares of Exscientia by 359.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock worth $34,000 after acquiring an additional 4,104 shares in the last quarter. Platinum Investment Management Ltd. raised its position in shares of Exscientia by 10.2% during the 3rd quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company’s stock worth $19,866,000 after acquiring an additional 405,426 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Exscientia during the 4th quarter worth about $207,000. Hedge funds and other institutional investors own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.